WILEY

BRAZIL Breast Cancer

Risk factors and treatment



Hormone positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (EBC)

EBC is a curable form of cancer that is contained in the breast or has only spread to the axillary lymph nodes[1]

Breast cancer cells express both oestrogen and progesterone receptors but lack HER2 receptors[1,2]

Tumours may exhibit endocrine therapy (ET) resistance and distant relapse[3]

Management must be multidisciplinary as treatments differ with molecular subtypes[1]

Why is risk assessment needed[1]?

Risk assessment must be done to determine

- Patients who need chemotherapy in addition to ET
- Optimal ET and its duration

Various risk factors governing HR+/HER2- EBC prognosis and treatment

ER+

Only a few patients (approximately <5% of all HR+ patients) show a very low expression (1–9%) of ER; these tumours have poor sensitivity to ET and should be treated as HR-

Clinico-pathological factors[5]

- Tumour grade
- Nodal status



Relapse risk[5]

- Directly impacts treatment choice
- Strongly correlated with original tumour nodal status

Recurrence score (RS)[6,7]

The TAILORx and RxPONDER studies showed that RS strongly governs the long-term benefits of chemotherapy in patients

↑Score ∞ ↑Relapse ∞ ↑Chemotherapy benefits

Genomic risk (determined using the 70-gene signature test)[8]

- Specific to individual tumour
- Categorises tumours into low- and high-genomic-risk types
- Directly impacts chemotherapy decision

Dynamic Ki-67 protein[9,10,11]

- Important proliferation marker
- Ki-67/MIB-1 ↑ ∞ Relapse risk ↑
- Predicts patient outcomes for adjuvant therapy: POETIC trial
- No optimised, clinically relevant cut-off value available
- Promising outcomes when coupled with RS

Visit https://breastcancer.knowledgehub.wiley.com/pt-br/ for additional resources

Various risk factors governing HR+/HER2- EBC prognosis and treatment

The clinical-pathologic stage + oestrogen receptor status, grade (CPS-EG) staging system for disease-specific survival[12,13]

- Categorises patients based on neoadjuvant therapy outcomes
- Can select candidates for post-neoadjuvant clinical trials
- Utilises the following criteria:
  - Clinico-pathologic stage
  - Oestrogen receptor status
  - Grade

Treatment strategies

Two pillars of EBC management[1]

Locoregional treatment (surgery + radiation)

Systemic therapy

European Society for Medical Oncology clinical living guidelines for systemic therapy for HR+/HER2- EBC[14]



Cyclin-dependent kinase 4/6 inhibitors

Abemaciclib[15,16]

- Approved standard adjuvant treatment
- Blocks cancer cell progression
- MonarchE study (2 years): ET + abemaciclib > ↑Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS)

Ribociclib[17]

- NATALEE study (3 years)
  - Ribociclib + ET vs. ET alone
  - 400 mg ribociclib/day
  - ↑IDFS and DRFS
  - Further investigations underway

Poly (ADP-ribose) polymerase inhibitors

Olaparib[18]

- Targets cancers with defects in homologous recombination repair by synthetic lethality
- Used to reduce recurrence in patients with breast cancer germline mutation(s)
- OlympiA study (3 years): Olaparib vs. placebo
  - ↑ Overall survival benefit
  - Manageable toxicity

Surgery of the axilla[19]

- Discussed at the 18th St. Gallen International Breast Cancer Conference held in March 2023, in Vienna, Austria
- Multiple studies underway for validation

Key message

A meticulous risk assessment and evaluation of clinico-pathological criteria must be conducted before deciding on the best systemic therapies for HR+/HER2- EBC

References

1. Harbeck, N., Penault-Llorca, F., Cortés, J., Gnant, M., Houssami, N., Poortmans, P., ... & Cardoso, F. (2019). Breast cancer. *Nature Reviews Disease Primers, 5*(1).
2. Shaw, G. (2008, December 4). Types of breast cancer. WebMD. https://www.webmd.com/breast-cancer/breast-cancer-types-er-positive-her2-positive.
3. Jin, X., Zhou, Y., Ma, D., Zhao, S., Lin, C., Xiao, Y., ... & Shao, Z. (2023). Molecular classification of hormone receptor-positive HER2-negative breast cancer. *Nature Genetics, 55*(10), 1696–1708.
4. Iwamoto, T., Booser, D. J., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., ... & Pusztai, L. (2012b). Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. *Journal of Clinical Oncology*, 30(7), 729–734.
5. Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Pető, R., Pritchard, K. I., Bergh, J., Dowsett, M., & Hayes, D. F. (2017). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *The New England Journal of Medicine*, *377*(19), 1836–1846.
6. JNCCN 360 - Breast - SABCS 2022: Long-term update from TAILORx in early-stage breast cancer. (n.d.). https://jnccn360.org/breast/news/sabcs-2022-long-term-update-from-tailorx-in-early-stage-breast-cancer/.
7. Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., . . . & Hortobágyi, G. N. (2021). 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. *The New England Journal of Medicine, 385*(25), 2336–2347.
8. Cardoso, F., Veer, L. J. V., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . & Piccart, M. (2016). 70-Gene Signature as an aid to treatment decisions in early-stage breast cancer. *The New England Journal of Medicine, 375*(8), 717–729.
9. De Azambuja, E., Cardoso, F., De Castro, G., Colozza, M. A., Mano, M. S., Durbecq, ... & Paesmans, M. (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. *British Journal of Cancer, 96*(10), 1504–1513.
10. Smith, I., Robertson, J. F. R., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C., ... & Dowsett, M. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. *Lancet Oncology, 21*(11), 1443–1454.
11. Mengel, M., Von Wasielewski, R., Wiese, B., Rüdiger, T., Müller-Hermelink, H. K., & Kreipe, H. (2002). Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. *The Journal of Pathology*, *198*(3), 292–299.
12. Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., González-Angulo, A. M., ... & Hunt, K. K. (2011). Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. *Journal of Clinical Oncology, 29*(15), 1956–1962.
13. Marmé, F., Lederer, B., Blohmer, J., Costa, S. D., Denkert, C., Eidtmann, H., ... & Schneeweiß, A. (2016). Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. *European Journal of Cancer*, 53, 65–74.
14. ESMO. (2022, May 18). Clinical practice guidelines on breast cancer. ESMO. https://www.esmo.org/guidelines/guidelines-by-topic/breast-cancer.
15. Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Álvarez, B. A., Amat, J., ... & Lallena, M. J. (2017). Preclinical characterization of abemaciclib in hormone receptor positive breast cancer. *Oncotarget, 8*(41), 69493–69507.
16. Sheffield, K. M., Peachey, J., Method, M., Grimes, B. R., Brown, J., Saverno, K., ... & Lee, K. (2022). A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. *Future Oncology, 18*(21), 2667–2682.
17. Slamon, D. J., Fasching, P. A., Hurvitz, S. A., Chia, S., Crown, J., MartíN, M., . . . & Hortobágyi, G. N. (2023). Rationale and trial design of NATALEE: a phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer. *Therapeutic Advances in Medical Oncology*, 15.
18. Tutt, A., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., . . . & Geyer, C. E. (2021). Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. *The New England Journal of Medicine, 384*(25), 2394–2405.
19. Curigliano, G., Burstein, H. J., Gnant, M., Loibl, S., Cameron, D., Regan, M. M., ... & Thürlimann, B. (2023). Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. *Annals of Oncology, 34*(11), 970–986.

Published by WILEY

Visit https://breastcancer.knowledgehub.wiley.com/pt-br/ for additional resources